Enlivex Ltd. amended its Senior Secured Convertible Promissory Note with Lind Global Asset Management XIV, LLC on August 11, 2026. The amendment waived a prior event of default related to market capitalization and increased the outstanding principal balance from approximately $16.3 million to $19.2 million. Monthly repayment obligations were reduced from approximately $2.3 million to $1.2 million, with maturity extended until full repayment. The conversion price was revised to the lower of $40.37625 or 80% of the average of the three lowest daily volume-weighted average prices over the preceding 20 trading days. A 10% interest rate applies if market capitalization remains below $75 million, and a reduced prepayment premium of 2.5% is available for six months. Enlivex Ltd. operates in the biotechnology industry, developing targeted therapies for cancer treatment.

On July 27, 2026, Enlivex Ltd. entered into a Securities Purchase Agreement with Rain Foundation to issue up to $800 million in ordinary shares or pre-funded warrants in a private placement. The initial tranche involves $400 million at $5.00 per share for fiat/stablecoin payments or $6.00 per share for RAIN tokens. The purchaser elected to fund the initial amount using RAIN tokens. Enlivex holds a put option to require the purchase of an additional $400 million over a 36-month period. Proceeds will fund RAIN ecosystem acquisitions, repay debt, and cover expenses. The transaction requires shareholder approval and Nasdaq compliance. Enlivex Ltd. operates in the digital asset and biotechnology sectors, focusing on the RAIN token ecosystem and cancer immunotherapy research.

On July 28, 2026, Enlivex Ltd. announced a private placement of $400 million in ordinary shares with a single institutional investor. Shares are priced at $5.00 for USD, USDT, or USD Coin subscriptions, and $6.00 for RAIN token subscriptions, representing premiums of 17.4% and 40.8% over the July 27 closing price. The investor initially elected to fund the purchase with RAIN tokens. The transaction includes a demand registration right allowing Enlivex to require the purchase of an additional $400 million over 36 months. Closing is contingent on shareholder approval under Nasdaq Listing Rules 5635(a) and 5635(b) and Israeli law. Enlivex is a longevity company advancing Allocetra immunotherapy and operating a prediction markets treasury.

As of July 18, 2026, Enlivex Ltd. reported a net asset value (NAV) per ordinary share of $66.16 and held 79,550,593,122 RAIN tokens with a total treasury valuation of approximately $1.1 billion. The company's treasury strategy is built around the Rain protocol on the Arbitrum network. Enlivex is a longevity company that develops clinical-stage immunotherapy for inflammatory conditions associated with aging.